on Epigenica AB
Epigenica AB Unveils EpiFinder™ GenomePro for Advanced Epigenomic Research
Epigenica AB, a leader in epigenomic innovation, has announced the release of EpiFinder™ GenomePro, a product that enhances advanced epigenomic research. This new platform allows simultaneous examination of histone post-translational modifications and DNA methylation, maintaining high throughput and cost efficiency.
EpiFinder™ GenomePro offers optimized reagents and shorter protocols, allowing for 24 samples to be analyzed in a single run. Researchers can now conduct large-scale studies more affordably with robust quantitative data from minimal sample volumes. This version supports 192 genome-wide Chromatin Immunoprecipitation Sequencing profiles.
CEO Mohamad Takwa envisions this product setting a new standard in epigenomic research, offering valuable insights that help in the understanding and treatment of diseases through novel biomarkers and precision therapies. The product's design allows flexibility, dealing with both hPTMs and DNA methylation, and includes an open-source data pipeline.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Epigenica AB news